ANXV conjugate / Annexin - LARVOL DELTA

Annexin announces success in the company’s cancer initiative (PRNewswire) - "Annexin Pharmaceuticals today announces important progress in the company's preclinical cancer research where the drug candidate ANXV has shown promising results as a transporter of chemotherapy drugs to kill cancer cells. Within the framework of Annexin's cancer initiative, the company has successfully produced a so-called conjugate where the drug candidate ANXV is chemically bound to a chemotherapy agent and together forms a new composite molecule."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer